<?xml version="1.0" encoding="UTF-8"?><lom xmlns="http://ltsc.ieee.org/xsd/LOM" xmlns:lomfr="http://www.lom-fr.fr/xsd/LOMFR" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://ltsc.ieee.org/xsd/LOM http://www.lom-fr.fr/xsd/lomfrv1.0/std/lomfr.xsd">
<general>
<identifier>
<catalog>Canal-U_Ocms</catalog>
<entry>1552</entry>
</identifier>
<title><string language="fre"><![CDATA[p53 , supresseur de tumeurs]]></string></title>
<language>FRE</language>
<description>
<string language="fre"><![CDATA[La p53: mise en évidence, réarrangement et invalidation du gène Le virus simien 40 (SV40) exprime un oncogène, l'antigène grand T (AgT), qui est capable de transformer des cellules en culture et d'induire des tumeurs chez l'animal. Dans les cellules transformées, cet antigène viral s'associe à la protéine p53. C'est ainsi qu'en étudiant l'AgT, on a découvert la protéine p53. Les animaux porteurs de tumeurs induites par le virus SV40 produisent des anticorps contre l'AgT. Or, ces animaux synthétisent également des anticorps contre la protéine p53. Des études ultérieures menées chez l'Homme ont montré qu'environ 10 % des patients atteints d'un cancer possèdent des anticorps dirigés contre la p53. Ces résultats indiquent que la présence d'anticorps circulants dirigés contre la p53 est en relation avec le développement d'une tumeur et non pas avec la présence d'une protéine virale. L'immunogénicité de la protéine p53 dans un contexte tumoral a permis aux chercheurs de disposer très rapidement d'anticorps polyclonaux et monoclonaux pour étudier cette protéine. Ces outils se sont avérés d'autant plus précieux que, comme nous l'avons vu lors de la première émission, c'est la stabilité de la protéine, et non le taux de transcription, qui entraîne une modification de sa quantité intracellulaire, en fonction des situations.]]></string></description>
<keyword><string language="fre"><![CDATA[gène]]></string></keyword><keyword><string language="fre"><![CDATA[p53]]></string></keyword><keyword><string language="fre"><![CDATA[invalidation]]></string></keyword><keyword><string language="fre"><![CDATA[knock out]]></string></keyword><keyword><string language="fre"><![CDATA[rearrangement]]></string></keyword>
<lomfr:documentType>
<lomfr:source>LOMFRv1.0</lomfr:source>
<lomfr:value>image en mouvement</lomfr:value>
</lomfr:documentType>
</general><lifeCycle>
<contribute>
<role>
<source>LOMv1.0</source>
<value>author</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 14:26:12
FN:Claude CARON DE FROMENTEL
N:CARON DE FROMENTEL;Claude;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/caron_de_fromentel_claude
ROLE:author
NOTE: Statut Chargée de Recherche 1ère classe INSERM, depuis 1993. Parcours Stages doctoral et post-doctoral dans le laboratoire d'Oncologie Moléculaire, dirigé par le Dr Pierre May (UPR275 CNRS, IRSC, Villejuif), 1982/1989. Affecté à l'UPR275 CNRS, 1989/1993. Détachement auprès de la société Rhône-Poulenc Rorer, 1993/1997. Affecté à l'U380 INSERM (ICGM, Paris), depuis 1997. Particularités Publications - Caron de Fromentel C., Nardeux P.C., Soussi T., Lavialle C., Estrade S., Carloni G., Chandrasekaran K. and Cassingena R. (1985). Epithelial HBL-100 cell line derived from the milk of an appearently healthy woman harbors SV40 genetic information. Exp. Cell Res., 160: 83-94. - Caron de Fromentel C., Viron A., Puvion E. and May P. (1986). SV40 large T-antigen and transformation related protein p53 are associated in situ with nuclear RNP structures containing hnRNA of transformed cells. Exp. Cell Res., 164 : 35-48. - Caron de Fromentel C., May-Lévin F., Mouriesse H., Lemerle J., Chandrasekaran K. and May P. (1987). Presence of circulating antibodies against the cellular protein p53 in a notable proportion of children with B cell lymphoma. Int. J. Cancer, 39 : 185-189. - Soussi T., Caron de Fromentel C., Méchali M., May P. and Kress M. (1987). Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene, 1: 71-78. - Soudon J., Vilarem M.J., Caron de Fromentel C., Gras M.P. and Larsen C.J. (1988). Absence d'expression du gène de la protéine p53 dans une lignée humaine issue d'une leucémie de type I. C.R. Acad. Sci., 306 : 35-38. - Soussi T., Caron de Fromentel C., Breugnot C. and May E. (1988). Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. Nucl. Acids Res., 16 : 11384. - Soussi T., Caron de Fromentel C., Stürzbecher H.W., Ullrich S., Jenkins J. and May P. (1989). Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with SV40 large T antigen and mammalian heat shock proteins 70. J. Virol., 63: 3894-3901. - Caron de Fromentel C., Soussi T. and May P. (1990). La protéine p53: de la biologie moléculaire à la clinique. Med. Sci., 6: 352-358. - Soussi T., Caron de Fromentel C. and May P. (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945-952. - Soudon J., Caron de Fromentel C., Bernard O. and Larsen C.J. (1991). Inactivation of the p53 gene expression by a splice donor site mutation in a human T-cell leukemia cell line. Leukemia, 5: 917-920. - Caron de Fromentel C. and Soussi T. (1992). TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes, Chromosomes and Cancer, 4: 1-15. - Caron de Fromentel C., Pakdel F., Chaput A., Baney C., May P. and Soussi T. (1992). Rainbow trout p53: cDNA cloning and biochemical characterization. Gene, 112: 241-245. - Brambilla E., Gazzeri S., Moro D., Caron de Fromentel C., Gouyer V., Jacrot M. and Brambilla C. (1993). Immunohistological study of p53 in human lung carcinomas. Am .J .Path., 143, 199-210. - Lubin R., Schlichtholz B., Bengoufa D., Zalcman G., Trédaniel J., Hirsch A., Caron de Fromentel C., Preudhomme C., Fenaux P., Fournier G., Mangin P., Laurent-Puig P., Pelletier G., Schlumberger M., Desgrandchamps F., Le Duc A., Peyrat J.P., Janin N., Bressac B. and Soussi T. (1993). Analysis of p53 antibodies in patients with various cancers defined B-cell epitopes of human p53: distribution on the primary structure and exposure on the protein surface. Cancer Res, 53, 5872-5876. - Gazzeri S., Brambilla E., Caron de Fromentel C., Gouyer V., Moro D., Perron P., Berger F. and Brambilla C. (1994). p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer, 58, 24-32. - Le Goas F., May P., Ronco P. and Caron de Fromentel C. (1997). cDNA cloning and immunological characterization of rabbit p53. Gene, 185, 169-173. - Caron de Fromentel C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil C., Teillaud J-L., Tocqué B. and Bracco L. (1999). Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene, 18, 551-558. - Mary M-N., Venot C., Caron de Fromentel C., Debussche L., Conseiller E., Cochet O., Gruel N., Teillaud J-L, Schweighoffer F., Tocqué B. and Bracco L. (1999). A tumor specific single chain antibody dependent gene expression system. Oncogene, 18, 559-564. - Gillet R., Grimber G., Bennoun M., Caron de Fromentel C., Briand P. and Joulin V. (2000). The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene, 19, 3498-3507. 
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2002-11-22</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>author</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 14:26:12
FN:Pierre MAY
N:MAY;Pierre;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/may_pierre
ROLE:author
NOTE: Statut Directeur de Recherche Emérite au CNRS Parcours 1952 - Attaché de Recherche au CNRS (France). 1959 - Chargé de Recherche au CNRS. 1962 - Maître de Recherche au CNRS. 1964/1965 - Visiting Scientist, Albert Einstein College of Medicine, New York, USA. 1er octobre 1964 au 31 mai 1965. 1976 - Visiting Scientist, NIAID, National Institutes of Health (Bethesda, Md USA) 9 juillet - 22 septembre. 1981/1982 - Responsable du Département de Virologie de l'IRSC, Villejuif (France). 1982/1992 - Directeur du Laboratoire d'Oncologie Moléculaire, UPR275, CNRS - IRSC, Villejuif (France). 1985 - Directeur de Recherche I, CNRS. 1994/2004 - Directeur de Recherche Emérite au CNRS. Prix 1992 Prix de la Savoie de la Ligue Nationale contre le Cancer. 1993 Prix de la Recherche du Comité du Val-de-Marne de la Ligue Nationale contre le Cancer. 1993 Prix Rosen de Cancérologie de la Fondation pour la Recherche Medicale Française. 1996 Prix Léopold Griffuel de l'Association pour la Recherche sur le Cancer. Particularités Contributions de Pierre May à la découverte de la proteine p53 et à la connaissance de son organisation structurale. Publications les plus significatives de Pierre May - Kress, M., May, E., Cassingena, R. and May, P. (1979). Simian virus 40-transformed cells express new species of proteins precipitable by anti- simian virus 40 tumor serum. J. Virol, 31: 472-482. - May, E., Kress, M., Lange, M. and May, P. (1980). New genetic infirmation expressed in SV40 transformed cells: characterization of 55 K proteins and evidence for unusual SV40 early mRNAs. Cold Spring Harbor Sumposium, 44: 189-199. - May, P., May, E., and Kress, M. (1982). Control of cellular levels of the transformation associated 53-55 K proteins. Advences in Viral Oncology, 2: 59-80. - Duthu, A., Ehrhart, J.C., Benchimol, S., Chandrasekaran, K. and May, P. (1985). p53-transformaton related protein: kinetics of synthesis and accumulation in SV40-infected primary mouse kidney cell cultures. Virology, 147: 275-286. - Caron de Fromentel, C., Viron, A., Puvion, E.and May, P. (1986). SV40-large T-antigen and transformation related protein p53 are associated in situ with nuclear RNP structures containing hn RNA of transformed cells. Exp. Cell Res., 164: 35-48. - Caron de Fromentel, C., May-Lévin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K. and May, P. (1987). Presence of circulating antibodies against the cellular protein p53 in a notable proportion of children with B cell lymphoma. Int. J. Cancer, 39: 1 - Soussi, T., Caron de Fromentel, C., Méchali, M., May, P. and Kress, M. (1987). Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene, 1: 71-78. - Ehrhart, J.C., Duthu, A., Ullrich, S., Appella, E. and May, P. (1988). Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/73 in a human osteosarcoma cell line. Oncogene, 3: 595-603. - Louis, J.M., McFarland, V.W., May, P. and Mora, P.T. (1988). The phosphoprotein p53 is down-regulated post-transcriptionally during embryogenesis in vertebrates. Biochimica &amp; Biophysica Acta, 950: 395-402. - Soussi, T., Bègue, A., Kress, M., Stehelin, D. and May, P. (1988). Nucleotide sequence of a cDNA encoding the Chicken p53 nuclear oncoprotein. Nucl.Acids Res., 16: 11383. - Soussi, T., Caron de Fromentel, C., Sturzbecher, H.W., Ullrich, S., Jenkins, J. and May, P. (1989). Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with SV40 large T antigen and mammalian heat shock proteins 70. J. Virology, 63: 3894-3901. - Romano, J.W., Ehrhart, J.C., Duthu, A., Kim;C.M., Appella, E. and May, P. (1989). Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene, 4: 1483-1488. - Caron de Fromentel, C., Soussi, T. et May, P. (1990). La protéine p53: De la biologie moléculaire à la clinique. Médecine Sciences, 6: 352-358. - Soussi, T., Caron de Fromentel, C. and May, P. (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945-952. - Caron de Fromentel, C., Padkel, C., Chapus, A., Baney, C., May, P. and Soussi, T. (1992). Rainbow trout p53: cDNA cloning and biochemical characterization. Gene 112: 241-245. - Duthu, A., Debuire, B., Romano, J., Ehrhart, J.C., Fiscella, M., May, E., Appella, E. and May, P. (1992). p53 mutations in Raji cells: Characterization and localization relative to other Burkitt's lymphomas. Oncogene, 8: 2161-2167. - Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J.J., May, P. and Oren, M. (1993). p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13: 1415-1423. - Biard, D.S.F., Martin, M., LeRhun, Y., Duthu, A., Lefaix, J.L., May, E. and May, P. (1994). Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Research, 54: 3361-3364. - LeRhun, Y., Duthu, A., Ehrhart, J.C., Michiels, F., May, E. and May, P. (1994). Directional selection associated with clonal expansion of p53 mutant cells during neoplastic development of carcinogen-treated rat embryo lung epithelial cells. Oncogene, 9: 263-271. - Soussi, T., and May, P. (1996) Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol., 260: 623-637. - Bourdon, J.C., Deguin-Chambon, V., Lelong, J.C., Dessen, P., May, P., Debuire, B. and May, E. (1997). Further characterisation of p53 - responsive element - Identification of new candidate genes for transactivation by p53. Oncogene, 14: 85-94. - Le Goas, F., May, P., Ronco, P.and Caron de Fromentel, C. (1997). cDNA cloning and immunological characterization of rabbit p53. Gene, 185: 169-173. - Dumaz, N., Duthu, A., Ehrhart, J.C., Drougard, Ch., Appella, E., Anderson, C.W., May, P., Sarasin, A. and Daya-Grosjean,L. (1997). Prolongated p53 protein accumulation in trichothiodystrophy fibroblasts is dependent on unrepaired pyrimidine dimers on the transcribed strand of cellular genes. Molecular Carcinogenesis, 20: 340-347. - May, P., Soussi, Th. (1997). Tumor suppressor p53, Editorial. Pathologie Biologie, 45, 781-784. - May, P. (1998). Apoptose: Editorial, Perspectives et Promesses. Médecine Sciences, 14, 6-8. - May, P., May, E. (1998). Protéine p53: de l'interaction avec les protéines virales à la pathogénie des cancers humains. Virologie, 2, 347-354. - May P. and May E. (1999). Twenty years of p53 research - Structural and functional aspect of the protein. Oncogene, 18: 7621-7636. - May P. (2000) Cell cycle control and cancer. Pathol. Biol., 48 : 171-173. Sociétés savantes 1985/1986 - Fogarty International Center's Scholar in Residence, NIH, Bethesda, USA. 1987/1988 - Membre de la "Commission Scientifique Spécialisée n° 1 (INSERM)". 1987 - présent - Membre de l'Editorial Board du journal "Oncogene". 1992/1993 Membre de la Commission de Recherche de l'Hôpital Paul Brousse (AP de Paris) à Villejuif. 
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2002-11-22</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>author</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 14:26:12
FN:Mounira CHELBI-ALIX
N:CHELBI-ALIX;Mounira;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/chelbi_alix_mounira
ROLE:author
NOTE: Statut Directeur de Recherche. Parcours Formation Universitaire : 1976 : Maîtrise de Biologie, Université PARIS VII 1977 : Diplôme d'Etude Approfondies de Biologie Moléculaire, Université PARIS VII 1980 : Thèse de Doctorat de troisième cycle, Université PARIS VII 1987 : Thèse de Doctorat d'Etat es sciences, Université PARIS VII Adresses professionnelles 1977-1978 :Stage de DEA, IBPC, Laboratoire D. Hayes, 13 rue P. et M. Curie, 75005 Paris 1978- 1980 : Boursière Ligue Nationale Contre le Cancer, IBPC, laboratoire M. Grunberg-Manago. 13 rue P. et M. Curie, 75005 Paris 1981 : Entrée au CNRS au grade de CR2, Chargée de Recherche 2ème classe 1985 : Passage au grade de CR1 Chargée de Recherche 1ère classe 1987-1993 : U245 INSERM, Hôpital St Antoine, 75011 Paris, Responsable de l'équipe?Mécanisme d'induction et d'action des interférons ? 1994-2001 :UPR 9051 CNRS, Hôpital St Louis ,75010 Paris, Responsable de l'équipe ?Rôle des corps nucléaires dans la réponse à l'interféron ? Depuis 1998 Directeur de Recherche 2ème classe CNRS 2001- UPR 9045 CNRS, Institut Lwoff , 7 rue Guy Moquet, 94801 Villejuif Responsable de l'équipe ?Rôle des protéines conjuguées à SUMO dans la réponse à l'interféron et aux agents thérapeutiques ? Editeur d'un spécial ? Oncogene ? "APL a curable tumor pathology, from RAR to PML nuclear bodies" Edition novembre 2001 Evaluation scientifique Evaluation d'Unités de recherche CNRS. Referee pour fondations ou associations (AIRC) et pour divers journaux incluant Oncogene, J. Biol. Chem, J. Virol, Exp. Cell Res. Particularités LISTE DES PUBLICATIONS 1 - Thang, M.N., Thang, D.C., Chelbi-Alix, M.K., Robert-Galliot, B., Commoy- Chevalier, M.J. and Chany, C. Human leukocyte interferon : relationship between molecular structure and species specificity. Proc. Natl. Acad. Sci. USA, 1979, 76, 3717-21. 2- Chelbi-Alix, M.K. and Thang, M.N. Separation of species of human and mouse interferons by polynucleotide - affinity chromatography. Methods in Enzymology, 1981, 78, 576-91. 3 -Chelbi-Alix, M.K., Alix, J.H., Expert-Besançon, A., Hayes, F., Branlant, C. Properties of ribosomes and RNA synthesized by E. Coli grown in the presence of ethionine ; normal maturation of E. Coli ribosomal RNA in the absence of methylation. Eur. J. Biochem., 1981, 115, 627-634. 4 -Chousterman, S., Bird, J., Yao, J.S., Chelbi-Alix, M.K., Giroud, J.P. and Thang, M.N. 2'5' oligoadenylate synthetase activity level : an interferon-induced enzyme in macrophage derived from normal or inflamed mice. Ann. Virol., 1984, 135E, 363-368. 5 -Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N. Heat-shock induced regulation of 2'5' oligoadenylate synthetase. Prog. Clin. Biol., 1985, 67-74. 6- Chelbi-Alix, M.K. and Thang, M.N. Chloroquine impairs the interferon-induced antiviral state without affecting the 2'5' oligoadenylate synthetase. J. Biol. Chem., 1985, 260, 7960-7964. 7- Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N. 2'5' oligoadenylate synthetase expression is induced in response to heat-shock. J. Biol. Chem., 1987, 262, 4806-4811. 8- Chelbi-Alix, M.K. and Thang, M.N. Multiple molecular forms of interferon display different specific activities in the induction of the antiviral state and 2'5' oligoadenylate synthetase. Biochem. Biophys. Res. Commun., 1986, 141, 1042-1050. 9-Chelbi-Alix, M.K. and Thang, M.N. Cloned human interferons a : differential affinities for polyinosinic acid and relationship between molecular structure and species specificity. Biochem. Biophys. Res. Commun., 1987, 145, 426-435. 10-Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N. 2'5'A synthetase activity is induced by a factor excreted in heat-shocked cells. Comparison of this factor with IFN. The Biology of the Interferon System (Cantell K. and Schellekens H. eds.), 1987, 557-562. 11-Boissard, C., Chelbi-Alix, M.K., Gali, P., Thang, M.N. and Rosselin, G. Mise en evidence du recepteur de l'interferon alpha sur la cellule cancereuse colique humaine en culture. C.R. Acad. Sci., 1989, 309, Série III, 485-492. 12-Chelbi-Alix, M.K., Boissard, C., Rosselin, G. and Thang, M.N. Le peptide intestinal vasoactif induit la 2'5'oligoadénylate synthétase et l'état antiviral dans les cellules du cancer du colon HT29. C.R. Acad. Sci., 1990, 310, Série III, 147-153. 13-Chelbi-Alix, M.K., Boissard, C., Sripati, C.E., Rosselin, G. and Thang, M.N. VIP induces in HT-29 cells 2'5' oligoadenylate synthetase and antiviral state via interferon a/b synthesis. Peptides, 1991, 12, 1085-1093. 14-Chelbi-Alix, M.K., Belforte, B., Saal, F., Lasneret, J., Peries, J., and Thang,M.N. The effects of poly(I).poly(C12U) and interferon on the multiplication of a mammalian type C oncornaretroviridae. J. Gen. Virol., 1992, 73, 2291-2297. 15 -Chelbi-Alix, M.K. and Chousterman, S. Ethanol induces 2'5'A synthetase and antiviral activities through beta interferon production. J. Biol. Chem., 1992, 267, 1741-1745. 16-Chelbi-Alix, M.K. , Pelaparat, D., Boissard, C., Rostène, W., and Thang, M.N. Induction by Vasoactive Intestinal Peptide of interferon a/b synthesis in glial cells but not in neurons. J. Cell. Physiol., 1994, 158, 47-54. 17-M.K. Chelbi-Alix, A. Fournier, D. Pelaparat, C. Boissard, W. Rostène and M.N. Thang. Vasoactive Intestinal Peptideis an inducer of interferon a/b synthesis. 1st international symposium on VIP, PACAP and related regulatory peptides from molecular biology to clinical applications. G. Rosselin, ed., 1994, pp 598-606. 18-Chelbi-Alix, M.K., and Sripati, C.E. Effect of insulin and DsRNA to induce interferon system and hsp 70 in fibroblast and epithelial cells in relation to their effects on cell growth. Exp. Cell. Res., 1994, 213, 383-390. 19-Koken, M., Linares-Cruz, G., Quignon, F., Chelbi-Alix, M.K., Sobczak-Thépot, J., Juhlin, L., Degos, L., Calvo, F., and de Thé, H. The PML growth-suppressor has an altered expression human oncogenesis. Oncogene, 1995, 10, 1315-1324. 20-Colas, S., Bourrges, J.F., Wybier-Franqui, J., Chelbi-Alix, M.K., Paul, P., Emanoil-Ravier, R. Human Foamy infection activates class I major histocompatibility complex antigen expression. J. Gen. Virol.,1995, 76, 661-667. 21-Puvion- Dutilleul, F., Chelbi-Alix, M.K., M. Koken, F. Quignon, E. Puvion, H. de Thé. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body -associated PML protein. Exp. Cell. Res., 1995, 218, 9-16. 22-Chelbi-Alix, M.K., L. Pelicano, F. Quignon, M. Koken, M. Stadler, J. Pavlovic, L. Degos, H. de Thé. Induction of PML by interferons in normal and APL cells. Leukemia, 1995, 9, 2027-2033. 23-Stadler, M., Chelbi-Alix, M.K., Koken, M.H.M., Venturini, L., Lee, C., Saïb, A., Quignon, F., Pelicano, L., Guillemin, M.C., Schindler, C. and de Thé, H. (1995) Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene, 1995, 11, 2565-2573. 24-Chelbi-Alix, M.K., L. Pelicano, F. Quignon, M. Koken, and H. de Thé (1996). PML is a primary target gene of interferon and could mediate some of its biological activities. Tumor Biology. Regulation of Cell Growth Differentiation and Genetics in Cancer, A. S. Tsiftsoglou, A.C., Sartorelli, D. E., Housman, T.M., Dexter, eds, 1996, Series H : Cell Biology, 99, pp 17-28. 25-André, C., Guillemin, M.C., Zhu J., Koken, M., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen, Z. and de Thé. The PML and PML/RARa domains : from autoimmunity to molecular oncology, and from retinoic acid to arsenic. Exp. Cell. Res., 1997, 229, 253-260. 26-Zhu J., Koken, M., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen, Z., and de Thé. Arsenic-induced PML targeting onto nuclear bodies, implications for the treatment of acute promyelocytic leukaemia. Proc. Natl. Acad. Sci. USA, 1997, 94, 3978-3983. 27-Pelicano, L., Li, F., Schindler, C. and M. K. Chelbi-Alix Retinoic acid induces interferon-induced proteins : Evidence of multiple mechanisms of action. Oncogene, 1997, 15, 2349-2359. 28-Koken M., Reid, A., Quignon, F., Chelbi-Alix, M.K., , Dong S., Chen Z., Davies J., Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF heterodimerize and colocalize to nuclear bodies. Proc. Natl. Acad. Sci. USA, 1997, 94, 10255-10260. 29-Gianni M., Koken MHM., Chelbi-Alix M.K., and de Thé. Isolation and characterization of an As2O3-resistant NB4 subline : rapid induction of apoptosis by retinoic acid. Blood, 1998, 91, 4300-4310. 30-Chelbi-Alix, M.K., Quignon, F., Pelicano, L., Koken, M and de Thé Virus resistance conferred by the interferon-induced Promyelocytic Leukemia protein. J. Virol., 1998, 72, 1043-1051. 31-Pelicano, L., and M. K. Chelbi-Alix L'acide rétinoïque et l'interféron dans le traitement des cancers humains : mécanismes d'action. Bulletin du Cancer, 1998, 85, 313-318. 32-Chelbi-Alix M.K., and de Thé Herpes virus proteasome-dependent degradation of nuclear bodies-associated PML and Sp100 proteins. Oncogene, 1999, 18, 935-941. 33-Pelicano L., Brumpt C., Pitha P.M. and Chelbi-Alix M.K . Retinoic Acid Resistance in NB4 APL cells is associated with lack of Interferon a synthesis, Stat1 and p48 induction. Oncogene, 1999, 18, 3944-3953. 34- Chelbi-Alix M.K., and L. Pelicano Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia, 1999, 13, 1167-1174. 35-Zhu J, Gianni M., Kopf, E., Honore, N., Chelbi-Alix M.K , Koken, M; Quignon F., Rochette-Egly, C., and H. de The. Retinoic acid induces proteasome-dependent degradation of Retinoic acid receptor a (RARa) and oncogenic RARa fusion proteins. Proc. Natl. Acad. Sci. USA, 1999, 96, 14807-14812. 36- Puvion-Dutilleul, F., Legrand, V., Mehtali, M., Chelbi-Alix M.K., de The, H., and E. Puvion. Deletion of the fiber gene induces the storage of hexon and penton base proteins in PML/Sp100-containing inclusions during adenovirus infection. Biology of the cell, 1999, 91, 617-628. 37- Pelicano L. and Chelbi-Alix M.. Interférons : signalisation et clinique. Regard sur la Biochimie, 1999, 2,15-28. 38- Bazarbachi A. , Nasr R., El-sabban M. E. , Mahe A. , Mahieux A., Mahieux R., Gessain A., Darwiche N. , Dbaido G., Kersual J. , Zermati Y. , Dianoux L. , Chelbi-Alix M. , de Thé H. , and hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia, 2000,14, 716-721. 39- Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M, Pelicci PG, Malorni W, Fiorucci G, Romeo G, Affabris E. Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells Oncogene, 2000, 44, 5041-53, . 40-Regad T,&amp; Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene. 2001, 49, 7274-86. 41- de The H, &amp; Chelbi-Alix MK APL, a model disease for cancer therapies? Oncogene. 2001, 49, 7136-9. 42- Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 2001, 13, 3495-505. 43-Danielle Blondel, Tarik Regad, Nicolas Poisson, Benjamin Pavie, Francis Harper, Pier P. Pandolfi, Hughes de Thé and Mounira K. Chelbi-Alix Rabies virus P and small P products interact directly with PML and disrupt PML nuclear bodies Oncogene, 2002, 21, 7957-70 44-Regad T, Chelbi-Alix MK. PML, un nouvel intermédiaire de l'effet antiviral de l'interféron. Med. Sci, 2002, 18, 25-27 45- Chelbi-Alix MK. Bobe P, Benoit G, Canova A &amp; R Pine Arsenic enhances the activation of Stat1 by interferon g leading to synergistic expression of IRF-1 Oncogene. In press 2003. 
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2002-11-22</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>publisher</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 14:26:12
FN:BioTV
N:BioTV;;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/biotv
ROLE:publisher
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2002-11-22</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>content provider</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 14:26:12
FN:BioTV
N:BioTV;;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/biotv
ROLE:content provider
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2002-11-22</dateTime></date>
</contribute>
</lifeCycle>
<metaMetadata>
<metadataSchema>LOMv1.0</metadataSchema>
<metadataSchema>LOMFRv1.0</metadataSchema>
</metaMetadata>
<technical>
<format>video/mp4</format>
<location><![CDATA[https://www.canal-u.tv/video/biotv/p53_supresseur_de_tumeurs.1552]]></location>
<location><![CDATA[https://streaming-canal-u.fmsh.fr/vod/media/canalu/videos/biotv/.p53.supresseur.de.tumeurs_1552/p53_supresseur_de_tumeurs.sd.mp4]]></location>
<size>249374405</size>
<duration><duration>PT0H25M29S</duration></duration>
</technical>
<educational>
<learningResourceType>
<source>LOMv1.0</source>
<value>lecture</value>
</learningResourceType>
<context>
<source>LOMv1.0</source>
<value>master</value>
</context>
</educational>
<rights>
<cost>
<source>LOMv1.0</source>
<value>no</value>
</cost>
<copyrightAndOtherRestrictions>
<source>LOMv1.0</source>
<value>no</value>
</copyrightAndOtherRestrictions>
<description>
<string language="fre"><![CDATA[Droits réservés à l'éditeur et aux auteurs. 
]]></string>
</description>
</rights>
<relation>
<kind>
<source>LOMv1.0</source>
<value>ispartof</value>
</kind>
<resource>
<identifier>
<catalog>URI</catalog>
<entry>https://www.canal-u.tv/producteurs/biotv/les_grandes_pathologies_du_xxie_siecle/le_cancer</entry>
</identifier>
<description>
<string language="fre"><![CDATA[LE CANCER]]></string>
</description>
</resource>
</relation>
<classification>
<purpose>
<source>LOMv1.0</source>
<value>discipline</value>
</purpose>
<taxonPath>
<source>
<string language="fre"><![CDATA[Universités Numériques Thématiques 2009 http://www.universites-numeriques.fr]]></string>
</source>
<taxon>
<id/>
<entry>
<string language="fre"/>
</entry>
</taxon>
</taxonPath>
</classification>
<classification>
<purpose>
<source>LOMv1.0</source>
<value>discipline</value>
</purpose>
<taxonPath>
<source>
<string language="fre">CDD 22e éd.</string>
<string language="eng">DDC 22nd ed.</string>
</source>
<taxon>
<id>615</id>
<entry>
<string language="fre"><![CDATA[Pharmacologie, thérapeutique, diagnostic]]></string>
</entry>
</taxon>
</taxonPath>
</classification> </lom>